Aspire Biopharma Holdings, Inc. reported on April 10, 2026, that stockholders approved a reverse stock split ranging from 1-for-5 to 1-for-500, increased authorized shares from 490M to 700M, and authorized issuance of shares beyond 19.99%. The approval votes were 2.1M for the reverse split and 1.9M for the authorized increase, marking a significant event for the company.